Therapeutic effect and safety of acipimox combined with small-dose atorvastatin on combined hyperlipidemia after renal transplantation / 器官移植

ABSTRACT

Objective To assess the therapeutic effect and safety of acipimox combined with small-dose atorvastatin on combined hyperlipidemia after renal transplantation. Methods Fifty-six patients complicated with combined hyperlipidemia after renal transplantation were randomized into the combined small-dose group [n =28,acipimox (250 mg,twice a day) +atorvastatin (1 0 mg,once a day)]and normal dose group [n =28,atorvastatin (20-40 mg,once a day)].Total cholesterol (TC),triglyceride (TG),high density lipoprotein cholesterin (HDL-C ), low density lipoprotein cholesterin (LDL-C ), aspartate aminotransaminase (AST),alanine aminotransferase (ALT),serum creatinine (Scr),blood urea nitrogen (BUN),uric acid (UA)and creatine kinase (CK)were observed before treatment and 1 ,2 and 3 months after treatment.Adverse drug reaction was recorded.Results Compared with those before treatment,TC,TG and LDL-C of the normal dose group and the combined small-dose group decreased after treatment,but HDL-C increased,and the difference had statistical significance (all in P <0.01 ).Compared with the normal dose group,TG and LDL-C of the combined small-dose group were lower and HDL-C was higher,and the difference had statistical significance (all in P <0.01 ).At each time point before and after treatment,ALT,AST,Scr, BUN,UA and CK of the normal dose group and the combined small-dose group showed no statistically significant difference (all in P >0.05).There was significant difference in the incidence of adverse reactions in the digestive system,nervous system,musculoskeletal system and skin/vascular of the normal dose group and the combined small-dose group (all in P <0.05 ).Conclusions Acipimox combined with small-dose atorvastatin can treat combined hyperlipidemia after renal transplantation safely and effectively.